Value Investor: CSL's growth injection

CSL investors should be pleased by the company's increased investment into research and development, which will solidify future earnings growth.

On October 27, CSL announced the $275 million acquisition of Novartis’ influenza vaccine business. The news excited investors, with CSL’s share price is up 5 per cent since the announcement. Their optimism is understandable: CSL’s past acquisitions have been very successful, achieving scale and operating leverage across the group.


SMS Code Sent…

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Looks you are already a member. Please enter your password to proceed

Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

Related Articles